MD One Ventures is a defense and national security-focused venture capital firm investing in early-stage dual-use technologies. Through its 'Randox for Builders' partnership, the firm actively backs breakthrough biotech, biosecurity, and diagnostic innovations that strengthen national resilience and public health infrastructure.
About MD One Ventures
MD One Ventures is a healthcare-focused early-stage venture firm investing in companies aligned with provider-side innovation, digital health, and clinical workflow categories. Public detail on fund size and stage discipline is somewhat limited, but the positioning suggests seed and Series A activity, with checks plausibly in the $500k to $3M range and the willingness to lead or participate. Healthcare exposure is the firm’s core thesis: physician founders building enterprise health software, clinician-facing AI tools, value-based care platforms, or behavioral health and chronic-care offerings are the natural fit. Founders building consumer wellness brands, therapeutics, or scaled growth-stage rounds should pitch elsewhere. Geographic posture is most likely US-led. The realistic entry path is a warm introduction from a clinician-investor, an existing portfolio founder, or a healthcare ecosystem operator with credibility on the provider side; cold outreach to a partner with a tightly framed clinical thesis can also produce a meeting. Founders should arrive with provider-side commercial signal, clinical credibility, and a defended unit economics model rather than a deck dominated by TAM. Treat MD One as a thesis-aligned healthcare partner that brings clinician network value and category fluency, and a credible co-investor or lead for early-stage provider-side software companies, particularly when the founder is themselves a clinician.
Founder reviews
Other portfolio companies
Companies in MD One Ventures's portfolio not currently in our directory.
Team
Pitch / review this investor
Have you raised from MD One Ventures? Founders only — share your honest experience (anonymous OK, moderated before publishing).